Hodgkin DiseaseLenalidomide
Dr. David Duane Hurd, MD
NPI1962481879
- Medicare services, 2022
- 237
- Part D claims, 2022
- 32
- Publications
- 23
- Clinical trials
- 4
- Industry payments
- $805
- Practice address
- 329 Nc-801 N, Advance, NC 27006
- Practice phone
- Call (336) 716-2255
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Find Dr. Hurd's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. David Duane Hurd is a medical oncologist in Advance, North Carolina
Dr. Hurd practices in Advance, North Carolina.
Dr. Hurd's NPI, 1962481879, was assigned on January 10, 2006. Dr. Hurd holds North Carolina license 38360.
NPI and contact details
- NPI
- 1962481879NPI Registry (opens in a new tab)
- NPI enumeration date
- January 10, 2006
- NPI status
- Active
- Practice phone
- (336) 716-2255
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 78
- Medical school graduation
- 1974
Sources: NPPES NPI Registry (CMS); and Dmand AI Professional Profile Data
Dr. David Duane Hurd's practice address is in Advance, North Carolina
Dr. Hurd's practice address in the NPI Registry is 329 Nc-801 N, Advance, NC 27006, in Davie County. The practice phone is (336) 716-2255.
- NPI Registry address329 Nc-801 N, Advance, NC 27006 · Davie CountyPhone(336) 716-2255
Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data
Dmand AI tracks the EHR system at Dr. David Duane Hurd's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hurd practices. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Dr. Hurd's practice | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every site where Dr. Hurd practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. David Duane Hurd is one of 203 medical oncologists in North Carolina
Medical oncology is Dr. Hurd's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Hurd is licensed in North Carolina.
Specialties and state licenses
- Medical oncology, North CarolinaPrimary
Medical oncologists near Dr. Hurd
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
203medical oncologists in North Carolina
8medical oncologists in Advance
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. David Duane Hurd billed Medicare for 237 services in 2022
CMS data shows 237 Medicare services from Dr. Hurd across 6 procedure codes in 2022. Medicare paid $19,713 for them. Every service was in a facility, such as a hospital, rather than an office.
Medicare services, 2022237
Paid by Medicare$19,713
Procedure codes6
Dr. Hurd's Medicare services by type, 2021 to 2022
- 2021
- 2022
- Office and hospital visits
- 2021: 3882022: 23739%
Dr. Hurd compared with the North Carolina median for medical oncologists, 2022
- Dr. Hurd
- North Carolina median
- Medicare services
- 237vs 52555% below
- Part D claims
- 32vs 36791% below
Medians across 199 medical oncologists in North Carolina with Dmand AI profiles that report each measure.
Dr. Hurd's most billed Medicare procedure codes, 2022
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Hurd?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Hurd and other medical oncologists in North Carolina.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. David Duane Hurd's patients have a median age of 73
Across all payers, Dmand AI patient panel data puts Dr. Hurd's median patient age at 73, with 60% women.
Dr. Hurd's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 73
Patient panel by sex, all payers
- Women60%
- Men40%
Source: Dmand AI Patient Panel Data
Dr. David Duane Hurd wrote 32 Medicare Part D claims in 2022
In 2022, Dr. Hurd wrote 32 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $515 in total drug cost. In 2021, CMS named 52 claims across 4 drugs.
Part D claims, 202232
Drugs named by CMS1
Total drug cost$515
Dr. Hurd's most prescribed drugs by claims, 2022
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2021 to 2022
- 2021
- 2022
- Claims for drugs CMS names
- 2021: 522022: 3238%
Drugs named by CMS: 1 in 2022, 4 in 2021.
Source: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026
For MedTech and pharma teams
Find medical oncologists like Dr. Hurd by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. David Duane Hurd has 23 publications on record
Dmand AI links 23 papers to Dr. Hurd, published from 2010 to 2024. 2013 was the busiest year, with 4. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Hematopoietic Stem Cell Transplantation and Lenalidomide. Dr. Hurd has published most often in Am J Hosp Palliat Care. Dr. Hurd's most frequent co-authors are Amanda Fishback Cashen, MD, Bruce David Cheson, MD and Hani Hassoun, MD.
Papers23
Years published2010 to 2024
Dr. Hurd's papers by year, 2013 to 2024
Topics Dr. Hurd writes about most
- Antineoplastic Combined Chemotherapy Protocols
- Hematopoietic Stem Cell Transplantation
- Lenalidomide
- Antineoplastic Agents
- Advance Care Planning
- Antimetabolites, Antineoplastic
- Cyclophosphamide
- Double-Blind Method
Dr. Hurd's most frequent co-authors
- Amanda Fishback Cashen, MD3 shared papers
- Bruce David Cheson, MD3 shared papers
- Hani Hassoun, MD3 shared papers
Recent publications by Dr. Hurd
N Engl J Med
Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBortezomib
Biol Blood Marrow Transplant
Antimetabolites, AntineoplasticAzacitidineHematopoietic Stem Cell Transplantation
See who Dr. Hurd researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Hurd works with, so you can find a warm path to the right medical oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. David Duane Hurd has worked on 4 clinical trials
Dmand AI links Dr. Hurd to 4 clinical trials, 2 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Multiple Myeloma and Blood Protein Disorders.
Clinical trials with Dr. Hurd by phase
- 2Phase 1: 2 trials
- 1Phase 2: 1 trial
- 1Phase 3: 1 trial
- NonePhase 4: no trials
Conditions in Dr. Hurd's trials
- Multiple Myeloma
- Blood Protein Disorders
Investigators on the most trials with Dr. Hurd
- Yvonne A. Efebera, MD2 shared trials
- Mounzer E. Agha, MD1 shared trial
- Melissa Alsina, MD1 shared trial
Recent clinical trials with Dr. Hurd
LCCC1841: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas (opens in a new tab)
Active, not recruitingPhase 2
Acalabrutinib
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma (opens in a new tab)
Active, not recruitingPhase 1
Multiple MyelomaBlood Protein DisordersDexamethasoneIbrutinibLenalidomide
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (opens in a new tab)
Active, not recruitingPhase 1
Multiple MyelomaBlood Protein DisordersBelantamab mafodotinBortezomibDexamethasone
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (opens in a new tab)
Active, not recruitingPhase 3
Multiple MyelomaBlood Protein DisordersBortezomibDexamethasoneLenalidomide
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. David Duane Hurd received $805 in industry payments from 2016 to 2023
CMS Open Payments shows 9 general payments to Dr. Hurd from 5 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 100% of the total. Genentech, Inc. paid the most, $317.
General payments to Dr. Hurd by program year, 2016 to 2023
Companies that paid Dr. Hurd the most, 2016 to 2023
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Sources for Dr. David Duane Hurd's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel Data |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. David Duane Hurd
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. David Duane Hurd's NPI number?
Dr. David Duane Hurd's NPI number is 1962481879. It was assigned on January 10, 2006, and it is active in the NPI Registry.
What kind of doctor is Dr. David Duane Hurd?
Dr. David Duane Hurd is a medical oncologist in Advance, North Carolina. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. David Duane Hurd practice?
Dr. Hurd practices at 329 Nc-801 N, Advance, NC 27006.
What is Dr. David Duane Hurd's office phone number?
The practice phone on file for Dr. Hurd is (336) 716-2255.
What is Dr. David Duane Hurd's medical license number?
Dr. Hurd holds North Carolina license 38360.
Does Dr. David Duane Hurd accept Medicare?
Yes. CMS data shows Dr. Hurd billed Medicare for 237 services in 2022.
What services does Dr. David Duane Hurd bill to Medicare?
In 2022, Dr. Hurd's most billed Medicare services were office visit, established patient (99214), office visit, established patient (99215) and hospital inpatient care (99232).
What drugs does Dr. David Duane Hurd prescribe most?
In 2022 Medicare Part D data, Dr. Hurd's most prescribed drugs by claims were Acyclovir.
Has Dr. David Duane Hurd received payments from drug or device companies?
CMS Open Payments shows $805 in general payments to Dr. Hurd from 5 companies from 2016 to 2023. The largest total came from Genentech, Inc.
How long has Dr. David Duane Hurd been practicing?
Dr. Hurd graduated from medical school in 1974, 52 years ago.
Does Dr. David Duane Hurd do research?
Dmand AI links 23 publications to Dr. Hurd, published from 2010 to 2024. Dr. Hurd has worked on 4 clinical trials.
Who does Dr. David Duane Hurd publish with?
Dr. Hurd's most frequent co-authors are Amanda Fishback Cashen, MD (3 shared papers), Bruce David Cheson, MD (3 shared papers) and Hani Hassoun, MD (3 shared papers).
Selling to medical oncology practices?
See medical oncologists in North Carolina by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card